Harstad E, Shults J, Barbaresi W, et al. - Researchers investigated preschool-age children with attention-deficit/hyperactivity disorder (ADHD) initiating α2-adrenergic agonist or stimulant medications in developmental-behavioral pediatric practices, for the frequency of reported improvement in ADHD symptoms and adverse effects linked with these medications. They conducted a retrospective review of health records of 497 children. As per data gained, 115 of 175 children (66%) receiving α2-adrenergic agonists and 251 of 322 children (78%) receiving stimulants had improvements, with differences in adverse effect profiles noted between medication classes. Those receiving α2-adrenergic agonists had only daytime sleepiness as more common relative to those receiving stimulants (38% vs 3%). There were reports of several adverse effects, encountered more commonly among those receiving stimulants vs α2-adrenergic agonists, including moodiness/irritability (50% vs 29%), appetite suppression (38% vs 7%), and difficulty sleeping (21% vs 11%).